✦ LIBER ✦

Re: Phase II Trial of Cetuximab with or Without Paclitaxel in Patients with Advanced Urothelial Tract Carcinoma

✍ Scribed by Hussain, Maha; Theodorescu, Dan

Book ID: 122253446
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 52 KB
Volume: 65
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2013.10.054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sorafenib in patients with advanced bili

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

✍ Bengala, C; Bertolini, F; Malavasi, N; Boni, C; Aitini, E; Dealis, C; Zironi, S; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 266 KB

A multi-institutional phase II trial of

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

✍ Donald S. Kaufman; Michael A. Carducci; Tim M. Kuzel; Mary B. Todd; William K. O 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Prospective Trial of Ifosfamide, Paclita

Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract

✍ Matthew D. Galsky; Alexia Iasonos; Svetlana Mironov; Joseph Scattergood; S. Mach 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 102 KB

A phase II trial of R115777, an oral far

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

✍ Jonathan E. Rosenberg; Hans von der Maase; John D. Seigne; Jozef Mardiak; David 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

Ifosfamide, paclitaxel, and cisplatin fo

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract : Final report of a Phase II trial evaluating two dosing schedules

✍ Dean F. Bajorin; John A. McCaffrey; Paul M. Dodd; Susan Hilton; Madhu Mazumdar; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## BACKGROUND. A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility

Commentary on “Phase II trial of cetuxim

Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA

✍ See, William A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 85 KB